MedPath

Study on Ex-PRESS Implantation Combined With Phacoemulsification in Primary Angle-closure Glaucoma

Not Applicable
Conditions
Glaucoma, Angle-Closure
Registration Number
NCT03323138
Lead Sponsor
Wenzhou Medical University
Brief Summary

Primary angle-closure glaucoma (PACG) is common, phacotrabeculectomy is associated with a significant risk of complications.The Ex-PRESS shunt was introduced as a modification to trabeculectomy, with the theoretical advantages of reduced complications.Our purpose is to perform a prospective study to evaluate the clinical outcomes and safety of the Ex-PRESS shunt with cataract surgery for PACG patients coexisting cataract.

Detailed Description

The Ex-PRESS is a miniature stainless steel glaucoma device, developed as an alternative to trabeculectomy mainly for patients with primary open-angle glaucoma.It has been proved to be as effective as trabeculectomy in a series of researches. However the early postoperative complication of Ex-PRESS implantation is less frequent compared with trabeculectomy. Ex-PRESS was designed initially for open angle glaucoma, gradually some scholars used it in refractory postpenetrating keratoplasty glaucoma and in vitrectomized glaucoma,which showed that Ex-PRESS shunt implantation was an effective procedure too. We analyzed the clinical efficacy and safety of combined phacoemulsification and Ex-PRESS implantation for PACG patients with cataract. Data was recorded before surgery and postoperatively at 1 week and 1, 3, 6, 12,18,24,30,36 months,which included intraocular pressure (IOP), best corrected visual acuity (BCVA), number of medications, complications, corneal endothelial cell density and anterior segment optical coherence tomography(AS-OCT). Efficacy was assessed by IOP values and success rates. Complete success was determined by IOP between 5 and 21mmHg without medications.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • The presence of PACG, angle peripheral anterior synechia (PAS) more than 180 degrees.
  • An indication for glaucoma filtering surgery based on uncontrolled IOP or progressive vision field defect despite antiglaucoma medications.
  • Mean vision field defect greater than 15dB.
  • The presence of a clinically significant decrease of visual acuity as a result of cataract, usually BCVA less than 0.6.
Exclusion Criteria
  • Patients unable to give informed consent.
  • Ocular infection or inflammation in the study eye in the 3 months prior to enrollment.
  • Intraocular surgery in the study eye in the 3 months prior to enrollment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Intraocular pressure (IOP)36 months

In millimeters of mercury (mmHg), measured with the Goldmann applanation tonometer

Secondary Outcome Measures
NameTimeMethod
Intraocular pressure (IOP)2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

In millimeters of mercury (mmHg), measured with the Goldmann applanation tonometer

Best corrected visual acuity (BCVA)2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

Number of lines reduction or improvement from baseline on Snellen acuity chart

Number of intraocular pressure lowering medications2 weeks, 1 month, 3 months, 6 months, 12 months,18 months, 24 months, 30 months,36 months.

Number of drops and oral medications used by the patient compared to baseline

Corneal endothelial cell density3 months

Use non-contact specular microscope to count the endothelial cell density (cells/mm2)

Angle opening distance(AOD500)3 months

Angle opening distance 500um from the scleral spur measured by AS-OCT

Anterior chamber distance(ACD)3 months

The distance from inner corneal surface to lens measured by AS-OCT

Trial Locations

Locations (1)

Ophthalmology and Optometry Hospital , Wenzhou Medical University

🇨🇳

Wenzhou, Zhejiang, China

Ophthalmology and Optometry Hospital , Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Li Nie, MD
Contact
+86-0571-86795959
nl@mail.eye.ac.cn

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.